The world’s first GLP-1 reduction treatment is being performed. administered for pets Experimentally.
OKV-119, an “extremely long-acting” GLP-1 implant being developed for weight management in cats, according to a press release, was successfully administered to the first cat in the MEOW-1 study.
OKAVA Pharmaceuticals, the San Francisco-based maker of the drug, says its groundbreaking clinical research on a “first-in-class” device will help treat diabetes, kidney disease, healthy aging and the longevity of your pet.
Click here to sign up for our health newsletter
The implant allows for continuous delivery of GLP-1 receptor agonists, extending it while improving cardiometabolic health and potentially “enhancing quality of life,” according to the release.
Once available, a single implant can be administered during your cat’s regular visit to the veterinarian. medicine delivery For up to 6 months.
The MEOW-1 trial is the first clinical study of its kind. weight loss Following breakthroughs in the use of GLP-1 for the management of obesity and diabetes in humans, it is also being used in cats and dogs.
OKAVA CEO Dr. Michael Klotzman said in a statement that calorie restriction, or fasting, “is one of the most established interventions.” extend lifespan and improve your cat’s metabolic health. ”
For more health stories, click here
“But it’s also one of the most difficult to maintain,” he says. “OKV-119 is designed to mimic many of the physiological effects of fasting. Improving insulin sensitivityIt can reduce fat mass and make energy metabolism more efficient. There’s no need to make major changes to your feeding routine or break the human-animal bond that revolves around food. ”
The MEOW-1 study aimed to evaluate the safety, tolerability, and efficacy of weight loss medications in overweight or obese cats. The researchers say the results will guide future clinical development and similar studies in dogs.
Dr. W. Chris Hummel, a veterinarian at Lovet Pet Health Care in Phoenix, Arizona, who was not involved in the study, confirmed that several GLP-1 drugs are being studied in livestock.
“Preliminary evidence suggests that GLP-1 and GLP-like drugs may be effective alternative therapy “Diabetes, also known as sugar diabetes, is one of the fastest growing diseases in dogs and cats, largely following the pet obesity epidemic,” he told Fox News Digital.
Test yourself with our latest lifestyle quiz
“Since the drug is administered by injection, long-acting combinations are currently being studied for efficacy and duration,” Hummel added. “The data is still early, but promising.”
